Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted ...

Investors in these stocks should be very aware that early-stage biotech stocks have huge ... Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends BioNTech Se.

The global acrocallosal syndrome therapeutics market a rare and complex genetic disorder characterized by agenesis of the corpus callosum, polydactyly, and distinct craniofacial anomalies—is set to ...

Protein Engineering Market IntroductionThe protein engineering market is rapidly evolving, driven by the need to develop proteins with improved functionality for a range of applications, including ...

Bay Area biotech company Tempest Therapeutics was once valued at more than $1 billion, but now it’s running out of gas. Last week, the cancer researcher revealed plans to lay off all but five ...

"Emerging blood-based diagnostics and disease-modifying therapeutics set to revolutionize Alzheimer's disease market, addressing public health crisis and economic burden." This in-depth analysis ...

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT ...

“Plus Therapeutics has multiple and significant opportunities in both the therapeutics and diagnostics markets with REYOBIQ™ (rhenium Re186 obisbemeda) and CNSide, and I believe it has ...